Metamizole as a Rare Cause of Drug-Induced Liver Injury

Nevena Preveden1,2, Matthias E Liechti3, Tobias Oettl1

  • 1Department of Internal Medicine, Gesundheitszentrum Fricktal, Rheinfelden, Switzerland.

Insights

Metamizole (dipyrone) is a rare cause of drug-induced liver injury (DILI). Prompt diagnosis and drug cessation are crucial for patient recovery and preventing future adverse events.

Area of Science:

  • Hepatology
  • Pharmacology
  • Internal Medicine

Background:

  • Drug-induced liver injury (DILI) presents diverse mechanisms and symptoms.
  • Metamizole (dipyrone) use is increasing in Europe, with limited data on its hepatotoxicity.
  • DILI is a diagnosis of exclusion, requiring thorough differential diagnosis.

Purpose of the Study:

  • To report a case of DILI attributed to metamizole.
  • To highlight the importance of detailed medical and drug history in DILI diagnosis.
  • To emphasize the need for patient awareness regarding metamizole's potential adverse effects.

Main Methods:

  • Case report of a 56-year-old male presenting with acute hepatitis.
  • Exclusion of other potential causes of liver injury, including infections and autoimmune diseases.
  • Liver biopsy confirming DILI, with subsequent cessation of metamizole.

Main Results:

  • The patient experienced recurrent hepatitis episodes linked to metamizole intake.
  • Liver biopsy confirmed drug-induced liver injury.
  • Discontinuation of metamizole resulted in rapid clinical improvement and normalized liver enzymes.

Conclusions:

  • Metamizole is identified as a rare cause of drug-induced liver injury.
  • Systematic medical and drug history is critical for diagnosing DILI.
  • Early recognition and withdrawal of the offending agent are essential for managing DILI.

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
211
Drug Metabolism: Phase I Reactions01:17

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.5K
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
4.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
263
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
857
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.7K